Svetlana E. Khatkova

Svetlana E. Khatkova

Auto-generated profile, based on publicly available information

Svetlana E. Khatkova

National Medical Research Center of Treatment and Rehabilitation

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
SKS.E. Khat’kOva
S.E. Khat’kOva
OPO.A. Pogorel’tSeva
O.A. Pogorel’tSeva
Stroke is a socially significant neurological disease, the second most common cause of disability and mortality. A wide range of neurological problems that occur after stroke: cognitive, motor, speech, and language disfunction, neuropsychiatric, swallowing disorders and others, complicate rehabilitation, impair social and everyday adaptation, and reduce the quality of life of patients and their caregivers. Cognitive impairment (CI) is one of the most significant and common complications of stroke. Stroke increases the risk of their development by 5-8 times. Dysphagia is also a common symptom of stroke, the cause of aspiration complications (pneumonia), and nutritional imbalance. It increases the possibility of developing CI and dementia, and contributes to an increase in mortality. Older adults with CI are at a higher risk of developing dysphagia, therefore the early symptoms of dysphagia (presbyphagia) should be diagnosed. In recent years, the connection between CI and dysphagia has been actively studied. It is extremely important to identify CI and swallowing disorders as early as possible in patients both before and at all stages after stroke; as well as to develop combined multidisciplinary protocols for the rehabilitation of patients with these disorders with pharmacological support for the process.

5 October 2023 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
OLOleg Levin
Oleg Levin
I(Igor Voznyuk (Voznjouk)
Igor Voznyuk (Voznjouk)
SISergey Illarioshkin
Sergey Illarioshkin
OTO.N. Tkacheva
O.N. Tkacheva
ABA.N. Bogolepova
A.N. Bogolepova
SYS.N. Yanishevskiy
S.N. Yanishevskiy
The aging of the population and the associated increase in the share of cognitive impairments in the structure of a wide range of diseases are a serious challenge for modern healthcare. Difficulties in the treatment of cognitive disorders are determined by many factors, including the age of patients, comorbidity, forced polypragmasia and the adequacy of the dosage of drugs that restore cognitive activity. The experts discussed information about the therapeutic potential of the drug Cerebrolysin in the treatment of cognitive disorders of various origins, stated significant experience of its effective and safe use in many clinical studies in mild and moderate forms of dementia. At the same time, there was a lack of consistent and systematic data on the dosage regimen, frequency, and duration of use of the drug in different forms of cognitive impairment and the degree of their severity. The aim of the international council of experts was to determine the optimal dosage regimens of the drug Cerebrolysin in patients with various etiologies and severity of cognitive impairment. The result of the work was the approval of a unified scheme for the use of the drug Cerebrolysin, considering the severity of the disease and its duration.

1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
SYS.N. Yanishevskiy
S.N. Yanishevskiy
SKS.E. Khatkova
S.E. Khatkova
В обзоре обсуждаются актуальные данные литературы об эффективности и безопасности реперфузионной и нейропротективной терапии при ишемическом инсульте (ИИ), а также роль нейропротекции на последующих этапах реабилитации. Авторы рекомендуют использовать индивидуальный подход к терапии больных с острым ИИ и выявлять пациентов, у которых нейротрофическая терапия принесет наибольший эффект. Также авторы отмечают, что фармакологическая поддержка является неотъемлемой частью реабилитации больных, перенесших ИИ, наряду с правильной оценкой неврологического дефицита, своевременным началом реабилитационных мероприятий, комплексностью и преемственностью на всех этапах.

30 April 2021 in Neurologia i Neurochirurgia Polska
Verified
Journal Article
Open access
PDF file
JHJulian Harriss
Julian Harriss
NRNicolas Roche
Nicolas Roche
CCCarlos Cantú-Brito
Carlos Cantú-Brito
SKSvetlana Khatkova
Svetlana Khatkova
PSPatrik Säterö
Patrik Säterö
Wolfgang JostWolfgang Jost
Wolfgang Jost
Aim of the study. SPACE, a prospective, non-interventional, open-label, multinational study, investigated physicians’ and subjects’ assessment of safety, efficacy, and health-related quality of life (HRQoL) following botulinum neurotoxin type A (BoNT-A) treatment to understand real-world clinical usage for the management of focal and multifocal spasticity. Clinical rationale for the study. Treatment guidelines recommend the use of BoNT-A for the management of spasticity in adults. This study assessed how physicians use BoNT-A therapy in real-world clinical practice, and provided evidence on long-term safety and efficacy over a period of up to 2 years. Materials and methods. BoNT treatment-naïve adults with spasticity of any aetiology received any BoNT-A formulation at their physician’s discretion, and were observed for ≤ 8 treatment cycles (≤ 2 years). Daily practice information, physician’s global assessments of tolerability and efficacy, and HRQoL were documented. Incidences of adverse drug reactions or all adverse events were documented for non-Mexican subjects and for Mexican subjects, respectively, due to protocol differences based on local regulatory requirements. Results. A total of 701 subjects were enrolled (safety population; nine countries). Physicians rated the tolerability of BoNT-A as ‘very good’ or ‘good’ for 88.2–97.4% of subjects throughout the study (subject numbers declined throughout this non-interventional study). Adverse drug reactions were reported for 16/600 (2.7%) of the non-Mexican subjects, with two considered to be ‘definitely related’ to treatment (injection-site haematoma, n = 1; botulism, n = 1). For 687 subjects, efficacy was rated ‘very good’ or ‘good’ by most physicians and subjects. Improvements in HRQoL were observed. Conclusions and clinical implications. Throughout this 2-year study, BoNT-A treatment was generally well-tolerated, effective, and associated with an improved HRQoL. This study makes a valuable contribution to the broader understanding of how physicians use BoNT-A therapy to manage spasticity in real-world clinical practice. Aim of the study. SPACE, a prospective, non-interventional, open-label, multinational study, investigated physicians’ and subjects’ assessment of safety, efficacy, and health-related quality of life (HRQoL) following botulinum neurotoxin type A (BoNT-A) treatment to understand real-world clinical usage for the management of focal and multifocal spasticity. Clinical rationale for the study. Treatment guidelines recommend the use of BoNT-A for the management of spasticity in adults. This study assessed how physicians use BoNT-A therapy in real-world clinical practice, and provided evidence on long-term safety and efficacy over a period of up to 2 years. Materials and methods. BoNT treatment-naïve adults with spasticity of any aetiology received any BoNT-A formulation at their physician’s discretion, and were observed for ≤ 8 treatment cycles (≤ 2 years). Daily practice information, physician’s global assessments of tolerability and efficacy, and HRQoL were documented. Incidences of adverse drug reactions or all adverse events were documented for non-Mexican subjects and for Mexican subjects, respectively, due to protocol differences based on local regulatory requirements. Results. A total of 701 subjects were enrolled (safety population; nine countries). Physicians rated the tolerability of BoNT-A as ‘very good’ or ‘good’ for 88.2–97.4% of subjects throughout the study (subject numbers declined throughout this non-interventional study). Adverse drug reactions were reported for 16/600 (2.7%) of the non-Mexican subjects, with two considered to be ‘definitely related’ to treatment (injection-site haematoma, n = 1; botulism, n = 1). For 687 subjects, efficacy was rated ‘very good’ or ‘good’ by most physicians and subjects. Improvements in HRQoL were observed. Conclusions and clinical implications. Throughout this 2-year study, BoNT-A treatment was generally well-tolerated, effective, and associated with an improved HRQoL. This study makes a valuable contribution to the broader understanding of how physicians use BoNT-A therapy to manage spasticity in real-world clinical practice.

23 April 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
SKS.E. Khatkova
S.E. Khatkova
OPO.A. Pogoreltseva
O.A. Pogoreltseva
OOOlga Orlova
Olga Orlova
ZKZ.N. Konovalova
Z.N. Konovalova
PYP.N. Yakovleva
P.N. Yakovleva
SNS.A. Novikov
S.A. Novikov
Objective. Evaluation of the safety and effectiveness of Relatox, botulinum toxin type A in patients with focal spasticity (FS) of the upper limb as a result of a cerebrovascular accident (CVA) or traumatic brain injury (TBI). Material and methods. A multicenter, prospective, single-blinded, randomized, comparative clinical study included 210 patients of both sexes aged 18—75 years after moderate to severe TBI and CVA in seven sites in the Russian Federation. The patients were randomized into two groups. Group 1 patients (n=105) with focal spasticity of the upper limb received Relatox injections into the muscles of the target pathological patterns (flexion of the elbow, hand, or fingers); Group 2 patients (n=105) received Dysport injections (reference agent). The drugs were injected with electromyographic (EMG) or ultrasound (US) control at a dose of no more than 400 Units of Relatox or 1000 Units of Dysport. Botulinum therapy was administered to patients for the first time or repeatedly, but not earlier than 3 months after CVA or TBI and 3 months (12 weeks) after the previous injection. At 4 and 12 weeks, spasticity was assessed using the Modified Ashworth Scale (MAS) for the muscles of the target spasticity pattern of the upper limb, the severity of disability was used to assess the Disability Assessment Scale (DAS), the severity of pain was evaluated using to the Numerical Pain Rating Scale (NPRS), and the satisfaction with treatment was measured by the Patient Global Impression of Improvement (PGI-I). The rate of adverse events (AEs) was reported. Results. A decrease in spasticity (decrease in MAS values) was shown in both groups without statistically significant intergroup differences at 4 weeks after injection for the muscles of the leading spasticity pattern of the upper limb (efficacy was assessed jointly for all target patterns) compared to the total score at the screening visit. The effect persisted for 12 weeks (more pronounced in the Relatox group). A significant decrease in pain severity according to the NPRS scale without significant intergroup differences was reported in both groups (slightly greater in Relatox group patients). The decrease in the mean DAS score with a statistically significant intergroup difference in hygiene, dressing, and overall well-being according to the PGI-I overall improvement scale was also greater in patients who received Relatox. Few local and systemic AEs were reported in both groups, with no intergroup differences. There were no significant deviations in laboratory parameters. Conclusion. The results indicate the safety, good tolerability, and efficacy of Relatox in patients with focal spasticity of the upper limb after focal brain damage due to CVA or TBI, comparable and even slightly longer in duration than those of Dysport, which supports its widespread use in the rehabilitation.

1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
SKS.E. Khatkova
S.E. Khatkova
OOOlga Orlova
Olga Orlova
DPD.V. Pokhabov
D.V. Pokhabov
VDV.P. Diagileva
V.P. Diagileva
SNS.A. Novikov
S.A. Novikov
ENE.A. Nikolaev
E.A. Nikolaev
The analysis of evaluation of the efficacy and safety of Relatox in patients with cervical dystonia (CD). Russian multicenter simple comparative randomized clinical trial. The study involved 180 patients of both sexes aged 18-65 years from 3 research centers of the Russian Federation. All patients had previously established diagnosis of CD and were randomized to one of two groups at 1 visit after the inclusion procedure and signing of informed consent. Patients in group 1 (n=90) got injections of Relatox, in group 2 (n=90) - injections of Botox for the first time or no earlier than 4 months after the previous injection of Dysport 500 units, Botox 200 units or Xeomin 200 units. The assessment of changes in cervical dystonia followed, including of determination of changes in the severity of CD, assessed on the TWSTRS scale by the total score and by the defining values of the blocks, as well as on the scales: the Patient Global Impression of Improvement (PGI-I) and of adverse events (local and systemic reactions). Based on the form of cervical dystonia (torticollis, laterocollis, etc.), the drug was injected under electromyographic control into the target muscles: sternocleidomastoid, belt, trapezoidal, shoulder-lifting muscle. Equal efficacy, good tolerability and safety comparable to the comparison drug Botox was demonstrated in 12 weeks after injection of Relatox. The number of registered local and systemic reactions in both groups was insignificant and did not differ significantly (p>0.05). There were no significant differences in the results of laboratory parameters in patients of both groups (p>0.05). Serious adverse events were also not detected during the study. Obtained results indicate the safety, good tolerability and efficacy of Relatox in patients with CD comparable to Botox and can be recomemded for using by practitioners.